Recombinant B lymphocytes expressing reassigned biological agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating diseases using B lymphocytes are limited in their ability to specifically target and effectively treat conditions such as cancer and autoimmune diseases, as they lack the specificity and efficacy in antigen recognition and cytotoxicity.
Innovation Solution
Development of recombinant B lymphocyte cell lines that express exogenously incorporated membrane immunoglobulins reactive to specific antigens, enabling them to produce secreted immunoglobulins and reassigned biological agents, such as cytokines, which can target and eliminate disease-specific cells through enhanced antigen presentation and cytotoxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional B lymphocyte methods are used for treating diseases, then the treatment approach is simple and straightforward, but the specificity and efficacy in antigen recognition and cytotoxicity are insufficient
Solution Approach 1:
The patent combines multiple functions into a single B lymphocyte cell line by simultaneously expressing membrane-bound immunoglobulin for antigen recognition and secreted cytokines for immune modulation. This merging of recognition and effector functions within one cell type resolves the contradiction by achieving high specificity through the membrane immunoglobulin while delivering therapeutic effect through the secreted cytokine, thereby improving reliability without requiring separate cell therapies
Solution Approach 2:
The modified B lymphocyte cell line is designed to perform multiple functions: antigen recognition via membrane-bound immunoglobulin, cytokine secretion for immune modulation, and antigen presentation. This multi-functionality allows a single cell type to address multiple aspects of disease treatment, improving both specificity for target antigens and overall efficacy while avoiding the complexity of coordinating multiple different cell therapies
2Reliability
If B lymphocytes are modified to express reassigned biological agents, then the therapeutic effectiveness is enhanced, but the manufacturing and genetic modification process becomes more complex
Solution Approach 1:
The patent employs preliminary action by first selecting and characterizing B lymphocyte cell lines with desirable baseline properties, then systematically introducing genetic modifications for membrane-bound immunoglobulin and cytokine expression. The use of established cell lines and standardized genetic engineering protocols performs preparatory work that simplifies subsequent manufacturing, thereby improving therapeutic effectiveness while managing manufacturing complexity
Solution Approach 2:
The patent applies parameter changes by modifying specific genetic parameters of B lymphocytes - introducing specific immunoglobulin and cytokine genes, controlling their expression levels, and optimizing their ratio. By systematically adjusting these genetic parameters rather than attempting comprehensive cell redesign, the patent achieves enhanced therapeutic effectiveness while maintaining relative ease of manufacture through targeted, rather than wholesale, modification
3Productivity
If recombinant B lymphocyte cell lines produce multiple immunoglobulins and biological agents, then the immune response is enhanced, but the complexity of cell function control increases
Solution Approach 1:
The modified B lymphocyte cell line utilizes the cell's own endogenous signaling pathways and regulatory mechanisms to control the expression and secretion of immunoglobulins and cytokines. The cell's natural activation, proliferation, and differentiation pathways automatically regulate the production of multiple biological agents in response to antigen stimulation, thereby enhancing immune response generation while avoiding the need for complex external control systems
Data Source
AI summary
Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated cytotoxic B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin capable of binding to a first antigen and at least one endogenous secreted immunoglobulin capable of binding to a second antigen, and further capable of expressing at least one exogenously incorporated recombinant B cell receptor that signals for expression of cytotoxic effector molecules.